Academic
Publications
FGFR4 Gly 388 Arg polymorphism contributes to prostate cancer development and progression: A meta-analysis of 2618 cases and 2305 controls

FGFR4 Gly 388 Arg polymorphism contributes to prostate cancer development and progression: A meta-analysis of 2618 cases and 2305 controls,10.1186/147

FGFR4 Gly 388 Arg polymorphism contributes to prostate cancer development and progression: A meta-analysis of 2618 cases and 2305 controls   (Citations: 1)
BibTex | RIS | RefWorks Download
Background  Fibroblast growth factor receptor 4 (FGFR4) displays multiple biological activities, including mitogenic and angiogenic activity, and plays important roles in the etiology and progression of prostate cancer. Gly388Arg polymorphism in FGFR4 gene has been reported to be involved in prostate cancer incidence and aggressiveness in several studies. To derive a more precise estimation of the relationship, a meta-analysis was performed. Methods  Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated to assess the association. Results  The Arg388 allele increased prostate cancer risk compared with Gly388 allele (OR = 1.17, 95% CI = 1.07-1.29). When stratified by race, there was a significantly increased prostate cancer risk in Asian and Caucasian populations. Moreover, prostate cancer patients with Arg/Arg genotype had a 1.34-fold increased risk of advanced prostate cancer (95% CI: 1.03-1.74) compared with those with Gly/Gly+Gly/Arg genotype. Conclusion  This meta-analysis showed the evidence that FGFR4 Gly388Arg polymorphism was associated with an increased risk of prostate cancer development and progression, suggesting that FGFR4 Gly388Arg polymorphism could be a marker for prostate cancer development and progression.
Journal: BMC Cancer , vol. 11, no. 1, pp. 1-6, 2011
Cumulative Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
Sort by: